[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peritoneal-dialysis-associated-peritonitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peritoneal-dialysis-associated-peritonitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100505354","phase-4-oral-vitamin-d-supplementation-prevent-peritoneal-dialysis-related-peritonitis-100505354",false,"NCT05860270","Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis","The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis, a Multicenter Randomized Controlled Trial","VD-PD","Inclusion Criteria:\n\n* Medically stable and receiving peritoneal dialysis for \\> 1 month\n* Older than 18 years old\n* Serum 25(OH)D \\\u003C 30ng\u002Fml\n* Adequate dialysis on evaluation with weekly Kt\u002FV ≥ 1.5, or (revised time: 2023-7-11) without clinical uremic symptoms\n\nExclusion Criteria:\n\n* Receive Vitamin D2\u002FD3 during the previous 1 month (revised time: 2023-7-11) ;\n* History of allergic reaction to Cholecalciferol;\n* Current or past malignant disease, active hepatitis or hepatic failure, active autoimmune disease, severe digestive malabsorption or an eating disorder, HIV\u002FAIDS;\n* Acute systemic infection, cardiovascular disease, surgery, or trauma in the last month;\n* A high probability of receiving a kidney transplant or transferring to hemodialysis or drop-out due to socioeconomic causes within 6 months;\n* History of kidney transplant;\n* Hemodialysis combined with peritoneal dialysis currently;\n* Pregnant or breastfeeding;\n* Not suitable enrolled assessed by researchers, including patients who could not regular follow-up","ALL","19 Years",{"count":20,"type":21},176,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a multicenter randomized, placebo-controlled trial of Vitamin D supplementation in patients on peritoneal dialysis to determine whether oral administration of vitamin D3 after curing an episode of peritonitis could reduce the risk of subsequent peritoneal dialysis-related peritonitis.",[27,28],"Peritoneal Dialysis-associated Peritonitis","Vitamin D Deficiency",[30,31,32],"Peritoneal dialysis","Peritonitis","Cholecalciferol","RECRUITING","2024-08-05",{"date":36,"type":37},"2024-08-06","ACTUAL",{"date":39,"type":37},"2023-06-15",{"date":41,"type":21},"2026-05-31",{"name":43,"class":44},"Peking University First Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":45},"100513904","phase-4-clinical-trial-on-antibiotic-lock-in-tenckhoff-catheter-for-relasping-and-repeat-peritonitis-100513904","NCT05971537","Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis","Inclusion Criteria:\n\n* PD patients who suffer from Either relapsing peritonitis (within 4 weeks of completion of antibiotics) or repeat peritonitis (between 4 to 12 weeks of completion of antibiotics), in which the causative organism is confirmed to be identical to the one in the preceding peritonitis episode, or Persistent growth of bacteria from PD effluent (PDE) after completion of standard 2-week antibiotic treatment, despite the resolution of symptoms and PDE leukocyte count \\\u003C100\u002Fmm3\n* Age \\> 18 years old\n* informed consent available\n\nExclusion Criteria:\n\n* Patients who do not respond to the appropriate IP antibiotics, evident by the persistence of peritonitis symptoms in which they should be referred for timely Tenchkoff catheter removal\n* Fungal or mycobacterial PD peritonitis\n* Co-existing exit site or tunnel tract infection\n* The presence of Tenckhoff catheter drainage dysfunction\n* \\\u003C= 3 years old\n* Pregnant patients",true,"18 Years",{"count":55,"type":21},46,[24],"Biofilm formation is an important cause of catheter-related infection. In hemodialysis, use of an antibiotic-lock has been proven to be effective to manage such a complication with preservation of the central venous catheter. In peritoneal dialysis, while biofilm has been implicated in relapsing and repeat peritonitis, both of which are caused by the identical bacteria as in their preceding peritonitis episode, no adjunctive measure has been proven to be effective to eradicate the biofilm bacteria. As a result, Tenckhoff catheter removal is the only recommended option for the patients suffering from relapsing or repeat peritonitis. In this study, the investigators are going to investigate whether the use of an antibiotic-lock can be useful to eradicate the biofilm in the Tenckhoff catheter to prevent future episodes of peritonitis caused by the same organism.",[27],"2024-01-29",{"date":61,"type":37},"2024-01-31",{"date":39,"type":37},{"date":64,"type":21},"2026-10",{"name":66,"class":44},"Alice Ho Miu Ling Nethersole Hospital"]